Overview

Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004

Status:
Active, not recruiting

Trial end date:
2023-07-25

Target enrollment:

Participant gender:

Summary

Study 20140114 will continue to follow subjects with GCTB who were treated in Study 20062004 and remained on the study at the completion of Study 20062004 for an additional 5 years on long-term safety follow up.

Phase:

Phase 4

Details

Lead Sponsor:

Amgen

Treatments:

Denosumab
Immunoglobulin G
Immunoglobulins